Equecabtagene Autoleucel
- Generic Name
- Equecabtagene Autoleucel
- Indication
用于治疗复发或难治性多发性骨髓瘤成人患者，既往经过至少3线治疗后进展（至少使用过一种蛋白酶体抑制剂及免疫调节剂）。
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Not Applicable
Recruiting
- Conditions
- Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
- Interventions
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06902844
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03)
Phase 3
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing GoBoard Boren Hospital, Beijing, China
🇨🇳Fu Xing Hospital, Capital Medical University, Beijing, China
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Not yet recruiting
- Conditions
- Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT06369935
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath